Physician profile
Jack F Ditty
NPI 1740315589
$3,493.43
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $578 · 2021: $836 · 2022: $563 · 2023: $608 · 2024: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.11 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,169.32 | 2019-2024 | Skyrizi |
| Janssen Biotech, INC. | $632.25 | 2020-2024 | Tremfya |
| Ucb, INC. | $527.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $390.58 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $199.44 | 2019-2023 | Ilumya |
| Lilly USA, LLC | $161.61 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.03 | 2022-2023 | Spevigo |
| Genzyme Corporation | $80.98 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $78.11 | 2022-2023 | Sotyktu |
| Pfizer INC. | $45.89 | 2021 | |
| Amgen INC. | $35.17 | 2019 | |
| Dermavant Sciences, INC. | $29.00 | 2022 | |
| Convatec INC. | $24.85 | 2024 | |
| Krystal Biotech INC | $21.48 | 2023 | Vyjuvek |
| Mylan Institutional INC. | $16.05 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Ditty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.